Heron Therapeutics Inc. (NASDAQ:HRTX) fell 2% on Thursday . The company traded as low as $19.62 and last traded at $19.93, with a volume of 875,075 shares traded. The stock had previously closed at $20.33.

A number of brokerages recently weighed in on HRTX. Cowen and Company restated a “buy” rating on shares of Heron Therapeutics in a research report on Saturday, July 9th. Jefferies Group reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Thursday, April 28th. Cantor Fitzgerald reiterated a “buy” rating on shares of Heron Therapeutics in a research report on Sunday, May 8th. Leerink Swann set a $33.00 price target on Heron Therapeutics and gave the company a “buy” rating in a research report on Thursday. Finally, Noble Financial reiterated a “buy” rating and issued a $51.00 price target on shares of Heron Therapeutics in a research report on Wednesday, April 20th. One investment analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Heron Therapeutics presently has an average rating of “Buy” and an average price target of $48.00.

The company’s 50 day moving average is $17.76 and its 200 day moving average is $18.86.

Heron Therapeutics (NASDAQ:HRTX) last issued its quarterly earnings data on Monday, August 8th. The biotechnology company reported ($1.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.96) by $0.21. On average, equities research analysts forecast that Heron Therapeutics Inc. will post ($3.89) earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the stock. Bank of Montreal Can purchased a new stake in Heron Therapeutics during the fourth quarter worth $3,010,000. GAM Holding AG increased its stake in Heron Therapeutics by 28.9% in the fourth quarter. GAM Holding AG now owns 41,900 shares of the biotechnology company’s stock worth $1,119,000 after buying an additional 9,400 shares during the last quarter. California Public Employees Retirement System increased its stake in Heron Therapeutics by 863.8% in the fourth quarter. California Public Employees Retirement System now owns 90,600 shares of the biotechnology company’s stock worth $2,419,000 after buying an additional 81,200 shares during the last quarter. Swiss National Bank purchased a new stake in Heron Therapeutics during the fourth quarter worth $1,100,000. Finally, California State Teachers Retirement System increased its stake in Heron Therapeutics by 1.9% in the fourth quarter. California State Teachers Retirement System now owns 54,211 shares of the biotechnology company’s stock worth $1,447,000 after buying an additional 1,000 shares during the last quarter.

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.